PMN400 / ProMIS Neurosci - LARVOL DELTA

ProMIS Neurosciences Achieves Milestone in Development of Therapeutic Alpha-Synuclein Vaccine (GlobeNewswire) - "ProMIS Neurosciences Inc...today announced the selection of a lead vaccine candidate, PMN400, against multiple synucleinopathies including Multiple System Atrophy (MSA), Parkinson’s disease and Lewy Body Dementia....Results from the vaccination studies are being submitted for presentation at the 2024 meeting of the American Academy of Neurology (AAN) taking place from April 13-18, 2024 in Denver, Colorado."

Pipeline update • Preclinical • CNS Disorders • Dementia • Lewy Body Disease • Multiple System Atrophy • Parkinson's Disease